Dendritic Cell Vaccines for Brain Tumors

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 139-157

  Kim, Won ^a   Liau, Linda M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumor; Cancer vaccines; Dendritic cells; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 23; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE DERIVATIVE; TOLL LIKE RECEPTOR AGONIST;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BRAIN TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; EDEMA; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY;

EID: 70450205309     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.09.005     Document Type: Review

References (72)

1. Mitchell D.A., Fecci P.E., and Sampson J.H. Immunotherapy of malignant brain tumors. Immunol Rev 222 (2008) 70-100
2. Aloisi F., Ria F., and Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21 (2000) 141-147
3. Parajuli P., and Sloan A.E. Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22 (2004) 405-416
4. Rodriguez A., Regnault A., Kleijmeer M., et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1 (1999) 362-368
5. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
6. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15 (1997) 821-850
7. Albert M.L., Jegathesan M., and Darnell R.B. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2 (2001) 1010-1017
8. Toes R.E., Ossendorp F., Offringa R., et al. CD4 T cells and their role in antitumor immune responses. J Exp Med 189 (1999) 753-756
9. Soling A., and Rainov N.G. Dendritic cell therapy of primary brain tumors. Mol Med 7 (2001) 659-667
10. Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med 14 (2008) 228-235
11. Steinman R.M., and Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94 (2001) 459-473
12. Figdor C.G., de Vries I.J., Lesterhuis W.J., et al. Dendritic cell immunotherapy: mapping the way. Nat Med 10 (2004) 475-480
13. Tschoep K., Manning T.C., Harlin H., et al. Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol 74 (2003) 69-80
14. De Vleeschouwer S., Fieuws S., Rutkowski S., et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14 (2008) 3098-3104
15. Yamanaka R., Homma J., Yajima N., et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 (2005) 4160-4167
16. Rutkowski S., De Vleeschouwer S., Kaempgen E., et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91 (2004) 1656-1662
17. De Vleeschouwer S., Van Calenbergh F., Demaerel P., et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100 (2004) 492-497
18. Barratt-Boyes S.M., Zimmer M.I., Harshyne L.A., et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 164 (2000) 2487-2495
19. Liau L.M., Black K.L., Prins R.M., et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 (1999) 1115-1124
20. Prins R.M., Odesa S.K., and Liau L.M. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63 (2003) 8487-8491
21. Grauer O.M., Sutmuller R.P., van Maren W., et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122 (2008) 1794-1802
22. Heimberger A.B., Crotty L.E., Archer G.E., et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103 (2000) 16-25
23. Ni H.T., Spellman S.R., Jean W.C., et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51 (2001) 1-9
24. Kim H.S., Choo Y.S., Koo T., et al. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 103 (2006) 142-148
25. Pellegatta S., Poliani P.L., Corno D., et al. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 28 (2006) 527-531
26. Jouanneau E., Poujol D., Gulia S., et al. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 55 (2006) 254-267
27. Akasaki Y., Kikuchi T., Homma S., et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother (1991) 24 (2001) 106-113
28. Yamanaka R., Zullo S.A., Tanaka R., et al. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94 (2001) 474-481
29. Yamanaka R., Yajima N., Tsuchiya N., et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J Neurosurg 97 (2002) 1184-1190
30. Aoki H., Mizuno M., Natsume A., et al. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50 (2001) 463-468
31. Bigner D.D., Pitts O.M., and Wikstrand C.J. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 55 (1981) 32-42
32. Liau L.M., Black K.L., Martin N.A., et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus 9 (2000) e8
33. Liau L.M., Prins R.M., Kiertscher S.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 (2005) 5515-5525
34. Yu J.S., Wheeler C.J., Zeltzer P.M., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 (2001) 842-847
35. Kikuchi T., Akasaki Y., Irie M., et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 (2001) 337-344
36. Kobayashi T., Yamanaka R., Homma J., et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52 (2003) 632-637
37. Yamanaka R., Abe T., Yajima N., et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 (2003) 1172-1179
38. Yamanaka R., Tsuchiya N., Yajima N., et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 99 (2003) 746-753
39. Wheeler C.J., Black K.L., Liu G., et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171 (2003) 4927-4933
40. Caruso D.A., Orme L.M., Neale A.M., et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6 (2004) 236-246
41. Yu J.S., Liu G., Ying H., et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 (2004) 4973-4979
42. Kikuchi T., Akasaki Y., Abe T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 (2004) 452-459
43. Walker D.G., Laherty R., Tomlinson F.H., et al. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 15 (2008) 114-121
44. Wheeler C.J., Black K.L., Liu G., et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68 (2008) 5955-5964
45. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138-147
46. Labeur M.S., Roters B., Pers B., et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162 (1999) 168-175
47. Wheeler C.J., Das A., Liu G., et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10 (2004) 5316-5326
48. Lake R.A., and Robinson B.W. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 5 (2005) 397-405
49. Kammula U.S., Marincola F.M., and Rosenberg S.A. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 92 (2000) 1336-1344
50. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
51. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009) 228-247
52. de Vleeschouwer S., Rapp M., Sorg R.V., et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59 (2006) 988-999 [discussion: 999-1000]
53. Sorg R.V., Ozcan Z., Brefort T., et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 26 (2003) 374-383
54. Thurner B., Roder C., Dieckmann D., et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223 (1999) 1-15
55. Tuyaerts S., Noppe S.M., Corthals J., et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 264 (2002) 135-151
56. Dauer M., Obermaier B., Herten J., et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170 (2003) 4069-4076
57. Yamanaka R., Zullo S.A., Ramsey J., et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 97 (2002) 611-618
58. De Vleeschouwer S., Van Gool S.W., and Van Calenbergh F. Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst 21 (2005) 7-18
59. De Vries I.J., Krooshoop D.J., Scharenborg N.M., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63 (2003) 12-17
60. Dhodapkar M.V., Krasovsky J., Steinman R.M., et al. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105 (2000) R9-14
61. Engell-Noerregaard L., Hansen T.H., Andersen M.H., et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58 (2009) 1-14
62. Fong L., Brockstedt D., Benike C., et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166 (2001) 4254-4259
63. Eggert A.A., Schreurs M.W., Boerman O.C., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 (1999) 3340-3345
64. Mackensen A., Krause T., Blum U., et al. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 48 (1999) 118-122
65. Morse M.A., Coleman R.E., Akabani G., et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 (1999) 56-58
66. Karman J., Ling C., Sandor M., et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 173 (2004) 2353-2361
67. Barratt-Boyes S.M., and Figdor C.G. Current issues in delivering DCs for immunotherapy. Cytotherapy 6 (2004) 105-110
68. Calzascia T., Masson F., Di Berardino-Besson W., et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22 (2005) 175-184
69. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64 (2005) 479-489
70. De Vleeschouwer S., Spencer Lopes I., Ceuppens J.L., et al. Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol 84 (2007) 131-140
71. Yamanaka R., Honma J., Tsuchiya N., et al. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 72 (2005) 107-113
72. Hu J., Yuan X., Belladonna M.L., et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 66 (2006) 8887-8896